Episode Summary

Dr. Greg Katz, preventive cardiologist at NYU Langone and co-host of Beyond Journal Club, joins Anish to dissect the online cholesterol debate — specifically the claims made by science communicator Nick Norwitz, who has maintained an LDL over 500 mg/dL on a low-carb diet for seven years with no coronary plaque on CTA. Katz takes the data point seriously, walks through the limitations of coronary CTA and the flawed Keto CTA study, and explains why he still believes the burden of proof lies with those arguing diet-induced hypercholesterolemia is safe — while acknowledging where the cardiology establishment, including the new lipid guidelines, overcorrects. The conversation covers the accountability gap between clinicians and content creators, the failure of risk calculators in young patients, and what a well-designed trial to actually answer this question would look like.

Chapter Markers

00:00 Introduction — Dr. Greg Katz, NYU Langone cardiologist and Beyond Journal Club co-host

01:40 What prompted the Substack: patients bringing in Nick Norwitz's content

02:51 Who is Nick Norwitz — LDL of 500, low-carb diet, and the clean CTA

05:38 Why Katz takes the question seriously but disagrees with the framing

08:01 Familial hypercholesterolemia outliers: why some FH patients never have events

10:05 The 50/50 problem — half of high-cholesterol patients have heart disease, half don't

12:27 The Jody Plute story: homozygous FH, Thomas Starzl, and the portacaval shunt experiments

17:37 Seven years of LDL 500 — is that long enough to know anything?

18:21 Limitations of coronary CTA: what it can and can't see

21:00 Why LDL gets put on a pedestal — and the cognitive dissonance of a diet that works

22:05 The conflict of interest argument — and why it cuts both ways

25:43 Burden of proof: mechanisms vs. outcomes data

27:16 Statins and GLP-1 levels — why a mechanistic claim isn't the same as a clinical outcome

31:38 Physician accountability vs. content creator accountability

35:24 The Keto CTA study: what it found, what it didn't, and why the blinding controversy matters

44:40 The new lipid guidelines: where they overcomplicate, where they overprescribe

49:38 GLP-1 deficiency framing and the over-medicalization of well people

55:54 Longevity medicine as "over-medicalization of well people"

57:35 What a well-designed trial would actually look like

1:00:01 Why the debate needs real research, not conjecture

1:02:37 How Katz talks to statin-hesitant patients in clinic

1:07:06 Wrap

Co-Host Handles

@anish_koka and @drdigiorgio

Show Handle

@drsloungepod

Subscribe Links

Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR

Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658

YouTube: https://www.youtube.com/@TheDoctorsLoungePod